{"editorial":{"content_id":"121530ca-6822-4565-bf07-d4b6b7cff766","slug":"article-20261016-14e054","content_type":"news","title":"巴西开发银行批准6亿雷亚尔贷款，支持布坦坦研究所建免疫生物制品工厂","summary":"巴西国家经济与社会发展银行批准向布坦坦研究所提供6亿雷亚尔融资，用于在圣保罗建设免疫生物制品最终加工中心，项目总投资预计10.6亿雷亚尔。","body":"巴西国家经济与社会发展银行（BNDES）批准向布坦坦研究所（Instituto Butantan）提供6亿雷亚尔融资，用于在圣保罗州建设免疫生物制品最终加工中心（CPFI 4）。该中心将生产疫苗和生物药物，项目总投资预计为10.6亿雷亚尔。\n\n这笔资金来自BNDES的「BNDES Mais Inovação」计划，将用于布坦坦研究所生产的免疫生物制品的配方、灌装、自动化检测和标签等环节。\n\n该中心计划生产的产品包括流感、新冠、HPV和甲型肝炎疫苗，以及用于治疗癌症、自身免疫疾病和多发性硬化症的单克隆抗体。可加工的药品包括用于自身免疫疾病的阿达木单抗、用于肿瘤治疗的帕博利珠单抗，以及用于多发性硬化症患者的那他珠单抗。\n\nCPFI 4建筑面积1.5万平方米，分两个生产楼层，将配备隔离器灌装线、疫苗处理和预充式注射器灌装等技术，预计年产能超过6亿剂液体剂量。\n\nBNDES行长阿洛伊齐奥·梅尔卡丹特表示，BNDES对该中心建设的支持将使巴西能够生产目前尚未在巴西生产的疫苗和生物药物，扩大通过统一医疗系统（SUS）向民众提供的治疗产品。布坦坦研究所副所长鲁伊·库里则认为，这笔融资对于扩大巴西在免疫生物制品生产方面的自主性、增强应对公共卫生需求的能力具有战略意义。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["金融","投资","行业趋势","br-health"],"content_level":"编辑整理","event_type":"金融投资","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-16T17:03:12.879Z","display_date":"2026-10-16","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/bndes-aprova-r-600-milhoes-para-fabrica-do-butantan/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/article-20261016-14e054","api_url":"https://chinabrazilinsight.com/api/public/content/article-20261016-14e054","markdown_url":"https://chinabrazilinsight.com/api/public/content/article-20261016-14e054?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/article-20261016-14e054?view=json","last_updated":"2026-10-16T17:03:35.670Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}